 | Complimentary Whitepaper: Automated Audit Management Best Practices
Learn how to:
• Reduce audit time and cost
• Mitigate risk
• Improve product quality and safety
• Facilitate compliance for industry regulations
Download Now. | |
| Health Care & Policy |  |  | | - Puma Biotechnology's breast cancer drug enters late-stage study
Puma Biotechnology has begun a late-stage trial of its lead drug candidate neratinib, or PB272, in patients with HER2-positive metastatic breast cancer who do not respond to two or more other drugs. The trial, which will involve around 600 patients, will be carried out at about 150 sites in the Asia-Pacific region, North America and Europe. RTT News (6/7)       - Fat can be source of ESC-like MUSE cells, study finds
Researchers at the University of California, Los Angeles, said they have discovered fat can be a source of stem cells that appear to be pluripotent. They have been named multilineage-differentiating stress-enduring, or MUSE, cells. The study, published in the journal PLOS One, said the cells appear to be more like embryonic stem cells than adult stem cells. The discovery may allow the use of fat from liposuction as a source for MUSE cells. NBC News/Vitals blog (6/5) - Neumedicines wins $8.3M to test radiation-sickness drug
The Biomedical Advanced Research and Development Authority awarded Neumedicines an additional $8.3 million to continue development of HemaMax, a recombinant human interleukin 12, as a treatment for bone marrow syndrome due to acute radiation sickness. Neumedicines will use the money to support preclinical studies. "With BARDA's continued funding we are moving HemaMax toward a possible pre-Emergency Use Authorization, which, if granted, could allow for its use in a national emergency," Neumedicines President and CEO Lena A. Basile said. Genetic Engineering & Biotechnology News (6/10)  | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Global Developments | | | | - Swiss regulators approve Roche's skin-cancer drug Erivedge
Swiss regulators granted Roche approval to market Erivedge, or vismodegib, as a treatment for advanced basal cell carcinoma. The drug was approved in the U.S. for the same indication in January. The approval triggers undisclosed milestone payments to partner Curis. Reuters (6/11) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Senate OKs farm bill with funding for energy programs
The Senate voted 66-27 to pass a version of the 2013 farm bill that includes mandatory funding for energy programs. "Farm Bill renewable energy and energy efficiency programs have a solid track record in supporting growth in agriculture, manufacturing, and new employment opportunities in rural America," said Lloyd Ritter, co-director of the Agriculture Energy Coalition. The House of Representatives is expected to take up its version next week. DomesticFuel.com (6/10), The Washington Post/Wonkblog (6/10)
| News from BIO | | | | - Industrial biotechnology with a French twist!
Over 1,300 leaders in biofuels, biobased products and renewable chemicals will be in Montreal June 16-19 for the 10th Annual BIO World Congress on Industrial Biotechnology. Join the impressive list of attendees for great food, excellent wine, and a can't miss program which will feature plenary sessions, breakout tracks, workshops, investor sessions, poster presentations, an exhibit hall, networking receptions, and business partnering. BIO is excited to bring this conference to Montreal, highlighting the industry's growth and the importance for generating green jobs and producing greener products and cleaner processes, all aimed at building a biobased economy. Learn more.
| SmartQuote | | | |  | Without the freedom to criticize, there is no true praise."
--Pierre Beaumarchais,
French playwright, inventor, diplomat and revolutionary  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, June 10, 2013
- Friday, June 07, 2013
- Thursday, June 06, 2013
- Wednesday, June 05, 2013
- Tuesday, June 04, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment